modified Peritoneal Equilibration test

PreclinicalBiologic

modified Peritoneal Equilibration test is one of 5 biologic programs targeting Peritoneal Dialysis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peritoneal DialysisUnknown status

Peritoneal DialysisPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Peritoneal Dialysis

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Phase 3

1 2

Bactroban

PPadagis LLC

Preclinical

1 3

Lotensin

VValidus Pharmaceuticals

Preclinical

1 4

Iron Isomaltoside

TThomas Jefferson University

Preclinical

1 5

modified Peritoneal Equilibration test

CCHU de Reims

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peritoneal Dialysis1 trial

Hydratation Status at Initiation of Peritoneal Dialysis: Study of the Role of Peritoneal Permeability

Unknown status·CCHU de Reims·N/A·NCT03322410·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for modified Peritoneal Equilibration test. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — modified Peritoneal Equilibration test compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for modified Peritoneal Equilibration test. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CHU de Reims company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCHU de Reims

modified Peritoneal Equilibration test

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peritoneal Dialysis1 trial

References

Drug Info

Quick Facts

Related News